Failure of recombinant activated factor VII during surgery in a hemophiliac with high-titer factor VIII antibody

Research output: Contribution to journalArticle

Abstract

Recombinant activated factor VII (rFVIIa) was used before and after inguinal hernioplasty to prevent bleeding in a patient with hemophilia. A complicated by a high-potency antifactor VIII inhibitor. rFVIIa (75 μg/kg) was given before and after surgery, first by bolus infusions at intervals of 2-3 h for 47 h and then by continuous intravenous infusion at a rate of 38 μg/h for an additional period of 12 h. Although no undue bleeding was observed during and for the first 26 h after surgery, the patient subsequently developed wound bleeding and hematomas that necessitated blood transfusion and infusion of porcine factor VIII. This case indicates that rFVIIa is not always successful in patients with antifactor VIII inhibitor and that more experience is needed to establish the optimal doses at surgery.

Original languageEnglish
Pages (from-to)1-4
Number of pages4
JournalHaemostasis
Volume21
Issue number1
Publication statusPublished - 1991

Fingerprint

Factor VIIa
Factor VIII
Hemorrhage
Antibodies
Groin
Herniorrhaphy
Hemophilia A
Intravenous Infusions
Blood Transfusion
Hematoma
Swine
Wounds and Injuries
recombinant FVIIa

ASJC Scopus subject areas

  • Hematology

Cite this

@article{9f8298ab7a544cca8da59faedfc04e77,
title = "Failure of recombinant activated factor VII during surgery in a hemophiliac with high-titer factor VIII antibody",
abstract = "Recombinant activated factor VII (rFVIIa) was used before and after inguinal hernioplasty to prevent bleeding in a patient with hemophilia. A complicated by a high-potency antifactor VIII inhibitor. rFVIIa (75 μg/kg) was given before and after surgery, first by bolus infusions at intervals of 2-3 h for 47 h and then by continuous intravenous infusion at a rate of 38 μg/h for an additional period of 12 h. Although no undue bleeding was observed during and for the first 26 h after surgery, the patient subsequently developed wound bleeding and hematomas that necessitated blood transfusion and infusion of porcine factor VIII. This case indicates that rFVIIa is not always successful in patients with antifactor VIII inhibitor and that more experience is needed to establish the optimal doses at surgery.",
author = "A. Gringeri and E. Santagostino and Mannucci, {P. M.}",
year = "1991",
language = "English",
volume = "21",
pages = "1--4",
journal = "Haemostasis",
issn = "0301-0147",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Failure of recombinant activated factor VII during surgery in a hemophiliac with high-titer factor VIII antibody

AU - Gringeri, A.

AU - Santagostino, E.

AU - Mannucci, P. M.

PY - 1991

Y1 - 1991

N2 - Recombinant activated factor VII (rFVIIa) was used before and after inguinal hernioplasty to prevent bleeding in a patient with hemophilia. A complicated by a high-potency antifactor VIII inhibitor. rFVIIa (75 μg/kg) was given before and after surgery, first by bolus infusions at intervals of 2-3 h for 47 h and then by continuous intravenous infusion at a rate of 38 μg/h for an additional period of 12 h. Although no undue bleeding was observed during and for the first 26 h after surgery, the patient subsequently developed wound bleeding and hematomas that necessitated blood transfusion and infusion of porcine factor VIII. This case indicates that rFVIIa is not always successful in patients with antifactor VIII inhibitor and that more experience is needed to establish the optimal doses at surgery.

AB - Recombinant activated factor VII (rFVIIa) was used before and after inguinal hernioplasty to prevent bleeding in a patient with hemophilia. A complicated by a high-potency antifactor VIII inhibitor. rFVIIa (75 μg/kg) was given before and after surgery, first by bolus infusions at intervals of 2-3 h for 47 h and then by continuous intravenous infusion at a rate of 38 μg/h for an additional period of 12 h. Although no undue bleeding was observed during and for the first 26 h after surgery, the patient subsequently developed wound bleeding and hematomas that necessitated blood transfusion and infusion of porcine factor VIII. This case indicates that rFVIIa is not always successful in patients with antifactor VIII inhibitor and that more experience is needed to establish the optimal doses at surgery.

UR - http://www.scopus.com/inward/record.url?scp=0025811146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025811146&partnerID=8YFLogxK

M3 - Article

C2 - 1907588

VL - 21

SP - 1

EP - 4

JO - Haemostasis

JF - Haemostasis

SN - 0301-0147

IS - 1

ER -